tbuckley/cabot-search huggingface dataset:
Medical Management vs Mechanical Thrombectomy for Mild Strokes
Authors: Nitin Goyal, Georgios Tsivgoulis, Konark Malhotra, Muhammad F. Ishfaq, Abhi Pandhi, Michael T. Frohler, Alejandro M. Spiotta, Mohammad Anadani, Marios Psychogios, Volker Maus, Adnan Siddiqui, Muhammad Waqas, Peter D. Schellinger, Marcel Groen, Christos Krogias, Daniel Richter, Maher Saqqur, Pablo Garcia-Bermejo, Maxim Mokin, Ronen Leker, Jose E. Cohen, Aristeidis H. Katsanos, Georgios Magoufis, Klearchos Psychogios, Vasileios Lioutas, Meg VanNostrand, Vijay K. Sharma, Maurizio Paciaroni, Alexandros Rentzos, Hazem Shoirah, J. Mocco, Christopher Nickele, Violiza Inoa, Daniel Hoit, Lucas Elijovich, Andrei V. Alexandrov, Adam S. Arthur
Journal: JAMA Neurology (2019)

The benefit of mechanical thrombectomy (MT) in patients with stroke presenting with mild deficits (National Institutes of Health Stroke Scale [NIHSS] score <6) owing to emergency large-vessel occlusion (ELVO) remains uncertain.To assess the outcomes of patients with mild-deficits ELVO (mELVO) treated with MT vs best medical management (bMM).We retrospectively pooled patients with mELVO during a 5-year period from 16 centers. A meta-analysis of studies reporting efficacy and safety outcomes with MT or bMM among patients with mELVO was also conducted. Data were analyzed between 2013 and 2017.We identified studies that enrolled patients with stroke (within 24 hours of symptom onset) with mELVO treated with MT or bMM.Efficacy outcomes included 3-month favorable functional outcome and 3-month functional independence that were defined as modified Rankin Scale scores of 0 to 1 and 0 to 2, respectively. Safety outcomes included 3-month mortality and symptomatic and asymptomatic intracranial hemorrhage (ICH).We evaluated a total of 251 patients with mELVO who were treated with MT (n = 138; 65 women; mean age, 65.2 years; median NIHSS score, 4; interquartile range [IQR], 3-5) or bMM (n = 113; 51 women; mean age, 64.8; median NIHSS score, 3; interquartile range [IQR], 2-4). The rate of asymptomatic ICH was lower in bMM (4.6% vs 17.5%; P = .002), while the rate of 3-month FI (after imputation of missing follow-up evaluations) was lower in MT (77.4% vs 88.5%; P = .02). The 2 groups did not differ in any other efficacy or safety outcomes. In multivariable analyses, MT was associated with higher odds of asymptomatic ICH (odds ratio [OR], 11.07; 95% CI, 1.31-93.53; P = .03). In the meta-analysis of 4 studies (843 patients), MT was associated with higher odds of symptomatic ICH in unadjusted analyses (OR, 5.52; 95% CI, 1.91-15.49; P = .002; I2 = 0%). This association did not retain its significance in adjusted analyses including 2 studies (OR, 2.06; 95% CI, 0.49-8.63; P = .32; I2 = 0%). The meta-analysis did not document any other independent associations between treatment groups and safety or efficacy outcomes.Our multicenter study coupled with the meta-analysis suggests similar outcomes of MT and bMM in patients with stroke with mELVO, but no conclusions about treatment effect can be made. The clinical equipoise can further be resolved by a randomized clinical trial.
Catheter Ablation Compared With Drug Therapy for Atrial Fibrillation
Authors: Norman C. Wang
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CS1-Specific Chimeric Antigen Receptor Drives Cord Blood NK Cell Maturation and Expansion In Vivo
Authors: Li Li, Muharrem Muftuoglu, Enli Liu, Sonny Ang, Jiangxing Lv, Xinhai Wan, Rong Cai, Han Chen, Bingqian Hu, Juan Jimenez, Duncan Mak, Jared K Burks, Mustafa H Bdiwi, Pinaki P Banerjee, Nobuhiko Imahashi, Lucila Nassif Kerbauy, Junjun Lu, Francesca Lorraine Wei Inng Lim, Mayela Carolina Mendt, April Depombo, May Daher, Rafet Basar, Sattva S. Neelapu, Robert Z. Orlowski, Michael Andreeff, David Costa Marin, Richard E Champlin, Elizabeth J Shpall, Katy Rezvani
Journal: Blood (2017)
Brain regulation of emotional conflict predicts antidepressant treatment response for depression
Authors: Gregory A. Fonzo, Amit Etkin, Yu Zhang, Wei Wu, Crystal Cooper, Cherise Chin-Fatt, Manish K. Jha, Joseph Trombello, Thilo Deckersbach, Phil Adams, Melvin McInnis, Patrick J. McGrath, Myrna M. Weissman, Maurizio Fava, Madhukar H. Trivedi
Journal: Nature Human Behaviour (2019)
Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD
Authors: Brent H. Koehn, Asim Saha, Cameron McDonald-Hyman, Michael Loschi, Govindarajan Thangavelu, Lie Ma, Michael Zaiken, Josh Dysthe, Walker Krepps, Jamie Panthera, Keli Hippen, Stephen C. Jameson, Jeffrey S. Miller, Matthew A. Cooper, Christopher J. Farady, Takao Iwawaki, Jenny P.-Y. Ting, Jonathan S. Serody, William J. Murphy, Geoffrey R. Hill, Peter J. Murray, Vincenzo Bronte, David H. Munn, Robert Zeiser, Bruce R. Blazar
Journal: Blood (2019)
Evaluation of Unexplained Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnostic Clinic
Authors: Shannon Nixon, Manjula Maganti, Ksenia Bezverbnaya, John Kuruvilla, Anca Prica, Robert Kridel, Vishal Kukreti, Patrick Gullane, Michael Reedijk, Melania Pintilie, Michael Crump
Journal: Blood (2018)
PTEN (phosphatase and tensin homologue deleted on chromosome 10) gain-of-function analysis in LNCaP prostate cancer cells
Authors: David J. Mulholland, Zhihong Wen, Satoko Kojima, Martin E. Gleave, Colleen C. Nelson, Michael E. Cox
Journal: Cancer Research (2005)

983  PTEN expression is frequently lost in advanced prostate cancer (PrCa). Mouse models with prostate specific loss of PTEN develop metastatic, androgen independent PrCa. However, ∼50% of lethal human PrCa continues to express PTEN indicating that prosurvival mechanisms are functional despite the presence of a major PI3K/Akt antagonist. In LNCaP PrCa cells, induction of apoptosis by PTEN is strongly opposed by androgens. However, androgen mediated genes that protect cells from PI3K/Akt antagonism are poorly understood. We have employed gain-of-function, stable LNCaP clones that inducibly express PTEN to assess: (1) alterations in PI3K/Akt signalling due to PTEN phosphatase activity and (2) the capacity for androgens to counteract an acute, PTEN mediated apoptotic response. Clones contained Tet-inducible expression constructs for PTEN WT or a catalytic mutant (C124S) and a VP16-Tet activator. LNCaP-PTEN and LNCaP-C124S cell stables were also made by lenti viral delivery of pLenti6/Tet repressor (TR) and a pDEST/TO/Lenti vector (Invitrogen). In charcoal-stripped serum (CSS) conditions, Doxycyclin (Dox; 2 ug/ml) efficiently induced WT PTEN and C124S PTEN expression, however, only WT PTEN effectively antagonized P-AktSer473/Thr308 and activated PARP cleavage. In CSS plus 1 nM R1881, WT PTEN diminished P-Akt, but did not activate PARP. Proliferation of LNCaP-WT PTEN cells cultured in CSS/Dox/1 nM R1881 for 7 days was 85% of growth in full serum conditions while growth of cells cultured in CSS/dox was 45% of control cultures. Soft agar assays confirmed that PTEN expressing LNCaP cells were tumourigenic in the presence of androgen. Nude mice harbouring subcutaneous LNCaP-PTEN/Matrigel xenografts with serum PSA levels of >50 ng/ml were administered Dox in drinking water ad libitum for 7 days. IHC analysis indicated PTEN expression in up to ∼70% of xenograft epithelium. Cells with high PTEN expression were also observed to have lower androgen receptor (AR) expression, suggesting an antagonistic interaction between androgens and PTEN. Gene expression was evaluated using an oligo microarray (14,000 spotted 70-mers) and Cy3 or Cy5 labelled cDNA generated from Dox treated (48 hours; 2 ug/ml) LNCaP-PTEN and LNCaP-C124S cells. Using GeneSpring 6.1 software our analysis considered: (1) the presence of serum; (2) the PTEN phosphatase function and (3) the presence of androgens. In addition to antagonizing PI3K, WT PTEN (but not C124S) induced apoptotic markers and decreased metabolic markers. Identification and characterization of genes associated with androgen mediated protection of PTEN expressing cells are presented and suggest how: (1) Stable, inducible integration has allowed evaluation of prolonged expression of PTEN expression in AR, PSA secreting PrCa cells and (2) how androgens prevent apoptosis and permit cell proliferation in the presence of PTEN for at least 7 days.
Abstract 15392: Therapeutic Benefit of a Novel GC-B Activator on Cardiac Remodeling in Experimental Chronic Kidney Disease
Authors: Yang Chen, Gerald E Harders, Tomoko Ichiki, John C Burnett, S. J Sangaralingham
Journal: Circulation (2017)

Introduction: Left ventricular hypertrophy (LVH) is a prevalent cardiovascular complication in chronic kidney disease (CKD) patients. Indeed, LVH is a strong risk factor for heart failure (HF) and ...
Who Heals the Healer?
Authors: Huma Farid
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiac Magnetic Resonance for Evaluating Nonculprit Lesions After Myocardial Infarction
Authors: Henk Everaars, Nina W. van der Hoeven, Gladys N. Janssens, Maarten A. van Leeuwen, Ramon B. van Loon, Stefan P. Schumacher, Ahmet Demirkiran, Mark B.M. Hofman, Rob J. van der Geest, Peter M. van de Ven, Marco J. Götte, Albert C. van Rossum, Niels van Royen, Robin Nijveldt
Journal: JACC. Cardiovascular imaging (2019)
Efficacy and dosimetry prognostic factors of image guided <sup>125</sup>I seed implantation for locally recurrent soft tissue sarcoma.
Authors: Weijuan Jiang, Ping Jiang, Ang Qu, Junjie Wang, Haitao Sun
Journal: Journal of Clinical Oncology (2019)

11073 Background: To observe the effect of ultrasound / CT guided radioactive 125 I seed implantation in the treatment of recurrent soft tissue sarcoma and its relationship with physical dosimetry prognostic factors. Methods: The data of 37 patients with recurrent soft tissue sarcoma who received ultrasound/CT-guided 125 I seed implantation from November 2005 to December 2015 were retrospectively analyzed. The local progression-free survival rate and overall survival rate were evaluated. The relationship of local progression-free survival rate and overall survival with physical dosimetric parameters was analyzed. Results: Thirty-seven patients, 20 males and 17 females, with a median age of 53 years (16-79 years), received a median radiation dose of 60 Gy (28 Gy-120 Gy). The median tumor volume was 46.8 cm 3 (0.5-252.2 cm 3 ), the median particle activity was 0.67 mCi (0.4-0.84 mCi), and the median implanted particle number was 60 (3-158). The median follow-up time was 20 months (range: 1~144 months). The median overall survival time was 20.0 months (95% CI 16.4-23.6 months). The overall survival rates of 1, 3 and 5 years were 62.2%, 34.3% and 27.7% respectively. The median local progression-free time was 63.0 months. The 1-year, 3-year and 5-year local progression-free survival rates were 68.9%, 55.0% and 47.1%, respectively. Correlation analysis showed that HI was positively correlated with total survival and local progression-free survival (P = 0.001). Multivariate analysis showed that HI ( &gt; 0.25) was an independent prognostic factor for long overall survival (P = 0.048, HR 0.39), and D 90 ( &gt; 110 Gy) was an independent prognostic factor for long local progression-free survival (P = 0.024, HR 0.17). Conclusions: Ultrasound/CT guided 125 I seed implantation is a safe and effective method for the treatment of recurrent soft tissue sarcoma with high local control rate. The HI and D 90 of the postoperative plan maybe affect the therapeutic efficacy.
Elevated Cardiometabolic Risk Profile Among Young Adults With Diabetes: Need for Action
Authors: Dana Dabelea, Richard F. Hamman
Journal: Diabetes Care (2019)

In this issue of Diabetes Care , Saydah et al. (1) from the Division of Diabetes Translation, Centers for Disease Control and Prevention, explore differences in demographic and cardiovascular disease risk factors in younger adults (18–44 years of age) and older adults (≥45 years) with diabetes compared with persons without diabetes. This is an important area for research, since, as documented recently by the SEARCH for Diabetes in Youth (SEARCH) study, prevalence (2) and incidence (3) trends are rising among youth for both type 1 diabetes (T1D) and especially type 2 diabetes (T2D), yet little work on the characteristics of younger adults with diabetes has been published.

Saydah et al. analyzed the U.S. National Health and Nutrition Examination Survey (NHANES) from 2007 to 2016, which included a representative sample of U.S. adults aged 18 years and older ( n = 23,798). Among younger persons with diabetes (mean age 36.4 years), with an average of 7.7 years of clinical diabetes duration, 29% had no health insurance, 22% had Medicaid-like plans, and only 65% reported having a usual place to receive care—all higher proportions than among persons without diabetes. They were also more likely to report living below the poverty line and being of minority race/ethnicity. Not surprisingly, persons with diabetes in both age-groups had higher adiposity, hypertension, and lipids and a poorer diet and less leisure-time physical activity than persons without diabetes in both age-groups. Perhaps more surprising, young adults with diabetes had significantly elevated lipids …
Dose and time effects of solar‐simulated ultraviolet radiation on the <i>in vivo</i> human skin transcriptome
Authors: M. Bustamante, C. Hernandez‐Ferrer, A. Tewari, Y. Sarria, G.I. Harrison, E. Puigdecanet, L. Nonell, W. Kang, M.R. Friedländer, X. Estivill, J.R. González, M. Nieuwenhuijsen, A.R. Young
Journal: British Journal of Dermatology (2019)

Terrestrial ultraviolet (UV) radiation causes erythema, oxidative stress, DNA mutations and skin cancer. Skin can adapt to these adverse effects by DNA repair, apoptosis, keratinization and tanning. To investigate the transcriptional response to fluorescent solar‐simulated radiation (FSSR) in sun‐sensitive human skin in vivo. Seven healthy male volunteers were exposed to 0, 3 and 6 standard erythemal doses (SED). Skin biopsies were taken at 6 h and 24 h after exposure. Gene and microRNA expression were quantified with next generation sequencing. A set of candidate genes was validated by quantitative polymerase chain reaction (qPCR); and wavelength dependence was examined in other volunteers through microarrays. The number of differentially expressed genes increased with FSSR dose and decreased between 6 and 24 h. Six hours after 6 SED, 4071 genes were differentially expressed, but only 16 genes were affected at 24 h after 3 SED. Genes for apoptosis and keratinization were prominent at 6 h, whereas inflammation and immunoregulation genes were predominant at 24 h. Validation by qPCR confirmed the altered expression of nine genes detected under all conditions; genes related to DNA repair and apoptosis; immunity and inflammation; pigmentation; and vitamin D synthesis. In general, candidate genes also responded to UVA1 (340–400 nm) and/or UVB (300 nm), but with variations in wavelength dependence and peak expression time. Only four microRNAs were differentially expressed by FSSR. The UV radiation doses of this acute study are readily achieved daily during holidays in the sun, suggesting that the skin transcriptional profile of 'typical' holiday makers is markedly deregulated. What's already known about this topic? The skin's transcriptional profile underpins its adverse (i.e. inflammation) and adaptive molecular, cellular and clinical responses (i.e. tanning, hyperkeratosis) to solar ultraviolet radiation. Few studies have assessed microRNA and gene expression in vivo in humans, and there is a lack of information on dose, time and waveband effects. What does this study add? Acute doses of fluorescent solar‐simulated radiation (FSSR), of similar magnitude to those received daily in holiday situations, markedly altered the skin's transcriptional profiles. The number of differentially expressed genes was FSSR‐dose‐dependent, reached a peak at 6 h and returned to baseline at 24 h. The initial transcriptional response involved apoptosis and keratinization, followed by inflammation and immune modulation. In these conditions, microRNA expression was less affected than gene expression.
Comparison of Circulating Tumor DNA Recovery from Plasma and Serum
Authors: Joanne Soo, David M. Kurtz, Michael Jin, Florian Scherer, Joseph G Schroers-Martin, Mohammad S Esfahani, Alexander Craig, Henning Stehr, Sattva S. Neelapu, Loretta Nastoupil, Mark Roschewski, Wyndham H. Wilson, Maximilian Diehn, Ash A. Alizadeh
Journal: Blood (2017)
Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America
Authors: Sandra Luna-Fineman, Guillermo Chantada, Amanda Alejos, Geraldina Amador, Margarita Barnoya, Mauricio E. Castellanos, Ligia Fu, Soad Fuentes-Alabi, Verónica Girón, Marco Antonio Goenz, Carlos Maldonado, Gustavo Méndez, Rosa Amelia Morales, Roberta Ortiz, Gissela Sanchez, Matthew Wilson, Carlos Rodríguez-Galindo
Journal: Journal of Clinical Oncology (2019)

Treatment abandonment because of enucleation refusal is a limitation of improving outcomes for children with retinoblastoma in countries with limited resources. Furthermore, many children present with buphthalmos and a high risk of globe rupture during enucleation. To address these unique circumstances, the AHOPCA II protocol introduced neoadjuvant chemotherapy with delayed enucleation.Patients with advanced unilateral intraocular disease (International Retinoblastoma Staging System [IRSS] stage I) were considered for upfront enucleation. Those with diffuse invasion of the choroid, postlaminar optic nerve, and/or anterior chamber invasion received six cycles of adjuvant chemotherapy (vincristine, carboplatin, and etoposide). Patients with buphthalmos and those with a perceived risk for enucleation refusal and/or abandonment were given two to three cycles of chemotherapy before scheduled enucleation followed by adjuvant chemotherapy to complete six cycles, regardless of pathology.A total of 161 patients had unilateral IRSS stage I disease; 102 underwent upfront enucleation, and 59 had delayed enucleation. The estimated 5-year abandonment-sensitive event-free and overall survival rates for the group were 0.81 ± 0.03 and 0.86 ± 0.03, respectively. The 5-year estimated abandonment-sensitive event-free survival rates for patients undergoing upfront and delayed enucleation were 0.89 ± 0.03 and 0.68 ± 0.06, respectively (P = .001). Compared with AHOPCA I, abandonment for patients with IRSS stage I retinoblastoma decreased from 16% to 4%.AHOPCA describes the results of advanced intraocular retinoblastoma treated with neoadjuvant chemotherapy. In eyes with buphthalmos and patients with risk of abandonment, neoadjuvant chemotherapy can be effective when followed by enucleation and adjuvant chemotherapy. Our study suggests that this approach can save patients with buphthalmos from ocular rupture and might reduce refusal of enucleation and abandonment.
Measurement of PD-1 Expression on Lymphoma Cells By Flow Cytometry Is a Useful Tool in Diagnosing and Monitoring Minimal Residual Disease in Angioimmunoblastic T-Cell Lymphoma
Authors: Mariko Yabe, Neval Ozkaya, Qi Gao, Janine Pichardo, Sarah Huet, Alison J. Moskowitz, Steven M. Horwitz, Ahmet Dogan, Mikhail Roshal
Journal: Blood (2017)
Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment
Authors: C. Gravalos, J. Sastre, E. Aranda, B. Massutí, M. E. Vega-Villegas, A. Gómez, M. Varella-Garcia, A. Jimeno, E. Díaz- Rubio, M. Hidalgo
Journal: Journal of Clinical Oncology (2007)

4120 Background: Our group has recently shown that single-agent cetuximab in first-line treatment of elderly MCRC pts has a favorable safety profile and similar activity to that observed in pretreated pts: 15% RR and 54% disease control (DC) (ESMO 2006: A324O). In this study, we aimed to identify predictive factors of clinical benefit from cetuximab without chemotherapy. Methods: This was a optional prospective ancillary study conducted in 36 of 41 pts included in the TTD 04–01 trial to explore potential predictive factors of response or resistance to single-agent cetuximab (400 mg/m 2 as initial dose and 250 mg/m 2 weekly thereafter). To this end we conducted a comprehensive analysis of potential predictive assays including polymorphisms of intron 1 of the EGFR gene, EGFR gene copy number by FISH (Varella-García Diagn Pathol 2006), IHC expression of signaling pathway proteins (EGFR, MAPK, AKT, PTEN), K-RAS, B-RAF, PI3KCA and PTEN mutations, as well as basal serum levels and dynamic changes of circulating EGFR after 4 weeks of treatment. Results: 9 of 41 pts (22%; 95%CI: 11–38) achieved DC at 12 weeks (2 CR, 4 PR, and 3 SD) with a median time to progression (TTP) of 8,3 months (range 4–11.3), similar to that observed with FOLFOX or FOLFIRI in first line treatment. Increased EGFR copy number (FISH+: scores 5–6) was observed in a total of 11 pts (11/36: 30,5%). Five of these 11 FISH+ pts had DC at 12w (45%) vs. 3 of 25 FISH- pts (12%) (p=0.04). No correlation was found between DC at 12w and polymorphisms of intron 1 of the EGFR gene, basal serum levels and dynamic changes of EGFR, IHC expression of pEGFR and pMAPK, or PI3KCA mutations. Analyses of PTEN and AKT by IHC, as well as K-RAS and PTEN mutations are ongoing. Conclusions: Although cetuximab provides higher efficacy in combination with chemotherapy, 22% of MCRC pts treated with monotherapy in first-line treatment present a remarkable median TTP of 8,3 months. This subgroup of pts can be selected in advance based on FISH+ combined or not with other possible predictive factors still under analysis. The full detailed analysis of data will be presented at the meeting. [Table: see text]